Group items tagged

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a new Johnson & Johnson drug in Britain. Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year. It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period. "Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

Are you unaware of the shocking truth about ‪‎Teens‬ being prescribed psychotropic ‪‎Drugs‬ without diagnosis in the US? Keep reading to learn more about teenage prescription drug use in the United States. Read our latest blog to find out!

Are you unaware of the shocking truth about ‪‎Teens‬ being prescribed psychotropic ‪‎Drugs‬ without diagnosis in the US? Keep reading to learn more about teenage prescription drug use in the United States. Read our latest blog to find out!